First AD

Second AD

Barriers to Implementing New CKD Treatments

What are the common barriers to implementing new CKD treatments and guidelines in clinical practice?

What role do pharmaceutical partners play in overcoming challenges in CKD treatment adoption?

Enhancing CKD Care in Type 2 Diabetes: Bridging Gaps in Diagnosis, Treatment, and Patient Outcomes

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

Chronic kidney disease (CKD) in Type 2 Diabetes patients necessitates early detection to prevent progression and associated complications. Identifying at-risk patients involves considering factors such as hypertension, family history of kidney disease, and elevated blood glucose levels. Screening tests include estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR). Early detection is crucial as it allows timely intervention, potentially slowing disease progression and reducing cardiovascular risks. CKD is a significant risk factor for heart failure, making early detection vital for comprehensive cardiovascular risk management.

Panelists discuss the common barriers to implementing new chronic kidney disease (CKD) treatments and guidelines in clinical practice, as well as the role of pharmaceutical partners in overcoming these challenges to enhance CKD treatment adoption.